These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24991448)

  • 21. Clostridium difficile infection: management strategies for a difficult disease.
    Khanna S; Pardi DS
    Therap Adv Gastroenterol; 2014 Mar; 7(2):72-86. PubMed ID: 24587820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and management of Clostridium difficile infection.
    Korman TM
    Semin Respir Crit Care Med; 2015 Feb; 36(1):31-43. PubMed ID: 25643269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updates on
    Grace E; Chahine EB
    Sr Care Pharm; 2019 Jan; 34(1):29-42. PubMed ID: 30821676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clostridium difficile infection: new insights into management.
    Khanna S; Pardi DS
    Mayo Clin Proc; 2012 Nov; 87(11):1106-17. PubMed ID: 23127735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
    Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M
    J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
    Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
    Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and opportunities in the management of Clostridium difficile infection.
    DuPont HL
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):863-74. PubMed ID: 25012255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
    Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
    Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].
    Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M
    Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clostridium difficile infection: review.
    Czepiel J; Dróżdż M; Pituch H; Kuijper EJ; Perucki W; Mielimonka A; Goldman S; Wultańska D; Garlicki A; Biesiada G
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1211-1221. PubMed ID: 30945014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clostridium difficile infection (CDI) in the course of time - an issue only for the internist?].
    Weis S; John E; Lippmann N; Mössner J; Lübbert C
    Zentralbl Chir; 2014 Aug; 139(4):460-8. PubMed ID: 24132675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.
    Marra F; Ng K
    Drugs; 2015 Jul; 75(10):1095-118. PubMed ID: 26113167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clostridium difficile cure with fecal microbiota transplantation in a child with Pompe disease: a case report.
    Dow DE; Seed PC
    J Med Case Rep; 2018 Apr; 12(1):112. PubMed ID: 29703246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complicated fecal microbiota transplantation in a tetraplegic patient with severe Clostridium difficile infection.
    Brechmann T; Swol J; Knop-Hammad V; Willert J; Aach M; Cruciger O; Schmiegel W; Schildhauer TA; Hamsen U
    World J Gastroenterol; 2015 Mar; 21(12):3736-40. PubMed ID: 25834343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection.
    Gens KD; Elshaboury RH; Holt JS
    J Pharm Pract; 2013 Oct; 26(5):498-505. PubMed ID: 23966282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
    You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of adult Clostridium difficile digestive contaminations: a literature review.
    Mathias F; Curti C; Montana M; Bornet C; Vanelle P
    Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):209-231. PubMed ID: 30498879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.